MedPath

Benefit of Left Atrial Roof Ablation in Paroxysmal Atrial Fibrillation

Phase 3
Completed
Conditions
Drug-refractory Paroxysmal Atrial Fibrillation
Registration Number
NCT01203241
Lead Sponsor
Hospital Clinic of Barcelona
Brief Summary

The aim of the present study is to assess whether left atrial roof ablation adds any benefit in the arrhythmia-free probability after paroxysmal atrial fibrillation ablation.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
120
Inclusion Criteria
  • Drug-refractory paroxysmal atrial fibrillation
Exclusion Criteria
  • Hypo or hyperthyroidism
  • Implantable defibrillation or pacemaker implanted
  • Moderate or severe mitral valve disease or mitral prosthetic valve
  • Ejection fraction less than 30%
  • Left atrial anteroposterior diameter more than 50 mm.
  • Previous atrial fibrillation ablation
  • Left atrium thrombus
  • Current infective disease or sepsis
  • Pregnant women
  • Current unstable angor
  • Acute myocardial infarction in last 3 months
  • Atrial fibrillation secondary to ionic disturbance, thyroids disease or secondary to any other reversible or non cardiovascular disease
  • Reduced expectancy of life (less than 12 months)
  • Patient participating in another clinical study that investigates a drug or device
  • Psychologically unstable patient or denies to give informed consent

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Freedom from atrial arrhythmias without antiarrhythmic drugs1-year follow-up
Secondary Outcome Measures
NameTimeMethod
Freedom from atrial arrhythmias with or without antiarrhythmic drugs1-year follow-up
Presence of any complications in the acute phase or during follow-up1-year follow-up

Trial Locations

Locations (1)

Hospital Clinic Universitari

🇪🇸

Barcelona, Spain

Hospital Clinic Universitari
🇪🇸Barcelona, Spain

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.